rologie i - European Congress of Virology

Recommendations

Info

5 th European Congress of Virologyness cases were sent weekly by sentinel GPs to the two Greek NationalInfluenza Centres. Specimens were also received from outpatients and hospitalisedcases. RNA was extracted from 36 influenza A(H3N2) strains. RTPCR and sequencing was performed and nucleotide sequences were usedfor the molecular and phylogenetic analysis using the neighbour joining(NJ) method implemented in MEGA 5.0. Results: phylogenetic analysisof Greek H3N2 strains indicated clustering within the Victoria/208 cladei.e. groups 3A, 3B, 3C and 6. Interestingly no isolates fell into the geneticPerth/16 clade characterized by the H3N2 component of the 2011 12influenza vaccine. Variations on antigenic sites accumulated on the A, E,C and D, while B antigenic sites were conserved. Amino acid analysis ofA/Athens/16/2012 strain revealed the emergence of 4 amino acid substitutionsin 2 different antigenic sites indicating potential antigenic drift. All ofthe Greek A(H3N2) examined strains possessed the L183H substitutionthat affected the HA receptor binding site. Variations were also observedon the N linked glycosylation sites of HA. All 2011 12 isolates hadan altered potential N linked glycosylation site at amino acids 144–146.Four Southern greek stains that belonged to the 3C phylogenetic group,also possessed an additional glycosylation site, due to substitution S45N.These alterations may have influenced the function of the glycoprotein ofthose viruses.Conclusion: Our findings confirmed the genetic instability of influenzatype A (H3N2) viruses and the importance of continuous molecular surveillancefor the effective management of viral epidemics.REF 378Molecular characterisation of Human Hepatitis E virus from ItalyGiuseppina LA ROSA 1 , Marta FRATINI 1 , Marcello IACONELLI 1 ,Michele MUSCILLO 1 , Simonetta DELLA LIBERA 1 , MicheleEQUESTRE 2 , Angela CANDIDO 2 , Stefania TAFFON 2 , PaolaCHIONNE 2 , Elisabetta MADONNA 2 , Stefano DETTORI 2 , RobertoGIUSEPPETTI 2 , Roberto BRUNI 2 , Anna Rita CICCAGLIONE 21 Department of Environment and Primary Prevention, Istituto Superioredi Sanità, Rome, ITALY; 2 Department of Infectious, Parasitic and ImmuneMediated Diseases, Istituto Superiore di Sanità, Rome, ITALYHuman hepatitis E virus (HEV) is an emerging pathogen in industrialisedcountries. We re analysed a collection of serum samples previouslyconfirmed as HEV positive by anti HEV IgM and IgG assays as well as byReal Time PCR, with the aim of shedding light on the molecular epidemiologyof HEV in Italy. Samples were analyzed by published and newlydesigned PCR assays, using four sets of primers targeting the ORF1 andORF2, followed by phylogenetic analysis. Despite the use of four differentassays, not all samples tested positive by nested PCR. Moreover,no single method was able to detect all positive samples. Most sequencesgrouped with genotype 1, and originated from patients who had travelledto endemic areas, while the minority belonged to genotype 3, and originatedfrom Italian patients with no travel history. Phylogenetic analysisshowed a match between sequences derived from patients with travel relatedHEV and sequences from the geographical regions in which infectionwas acquired (mostly Bangladesh and India). Sequences from patientswith no travel history clustered on the same branch with published swineHEV isolates. Although autochthonous cases do occur, this study confirmsthat HEV in Italy is predominantly travel related. Broad range methodsfor molecular diagnosis of HEV are still in need of improvement. Thestudy was co funded by the Italian National Centre for the Prevention andControl of Diseases (CCM) project Hepatitis E Surveillance in Italy: anemerging disease in industrialised countries, and by the EU 7th Frameworkprogramme PREDEMICS project.REF 379Human Hepatitis E virus in urban wastewaters in ItalyGiuseppina LA ROSA, Marta FRATINI, Marcello IACONELLI,Simonetta DELLA LIBERA, Michele MUSCILLODepartment of Environment and Primary Prevention, Istituto Superiore diSanità, Rome, ITALYIn industrialised countries, Hepatitis E infection (HEV) is usuallyassociated with travel to endemic areas, but a growing number of sporadiccases are also seen in patients with no travel history. The objective ofthe present study was to investigate the occurrence of HEV in Italythrough the molecular screening of raw sewage samples collected fromurban wastewater treatment plants (WTPs). Three sets of broad rangePCR primers targeting the ORF1 (MTase and RdRp) and ORF2 (capsid)were used to examine 200 sewage samples collected throughout Italy(38 WTPs). PCR products were then subjected to sequencing andphylogenetic analysis. Despite the use of different assays, HEV RNAwas detected only in two samples, both belonging to genotype 3. On thephylogenetic tree, sequences clustered on the same branch with HEVisolates identified in serum samples of Italian patients with autochthonousHEV (no travel history). Although different studies indicate that HEVin Italy is predominantly travel related, in this study no genotype 1was detected. The study was co funded by the Italian National Centrefor the Prevention and Control of Diseases (CCM) project Hepatitis ESurveillance in Italy: an emerging disease in industrialised countries, andby the EU 7th Framework programme PREDEMICS project.REF 380High seroprevalence of Hepatits E virus among Egyptian BloodDonorsLobna METWALLY 2 , Endale TADESSE 1 , Alaa El Din SAAD ABD ELHAMID 31 Department of Medical Laboratory Science, College of Medicineand Health Sciences, Hawassa University, Hawassa, ETHIOPIA;2 Department of Microbiology, Faculty of Medicine, Suez Canal University,Ismailia, EGYPT; 3 Department of Clinical Pathology, Faculty of Medicine,Suez Canal University, Ismailia, EGYPTAim: the aim of this study was to assess seroprevalence of hepatitis E virus(HEV) among blood donors attending blood transfusion center of SuezCanal University Hospital during the study period. Method: 488 subjectsconsisted of 137 anti HCV positive donors, 35 HBsAg positive donors, and316 blood donors who were negative HBsAg, anti HCV and HIV attendingSuez Canal University Hospital blood transfusion center were included inthis study. All the study subjects were tested for anti HEV by ELISA andthe positive samples were further tested for HEV RNA by reveres transcriptasepolymerase chain reaction (RT PCR) method. Results: in a total of488 subjects, 102 (20.9%) were positive for anti HEV by ELISA. Anti HEVwas detected in (56/316) 17.7%, (10/35) 28.57%, and (36/137)26.28%, ofblood donors negative for both HBsAg & Anti HCV, HBsAg positive andAnti HCV positive donors, respectively. No significant (P>0.05) associationwas found between anti HEV positivity and HBsAg positivity andanti HCV positivity subjects. Anti HEV among blood donors with normalALT level (40) who were negative for HCV Ab, HBs Ag, and HIVwas 19.6%(43/219) and 13.4%(13/97) respectively. There was no statisticalsignificance (P>0.05) between the increase ALT level and Anti HEV.Conclusion: Seroprevalence of HEV antibody among blood donors in ourstudy in Ismailia, Egypt is high, but we cannot recommend screening of allblood donors for HEV until more data becomes available and until moreis known about the parenteral rout of transmission of HEV.Virologie, Vol 17, supplément 2, septembre 2013S225
5 th European Congress of VirologyREF 381Phylogenetic analysis in an outbreak of Echovirus 30 aseptic meningitisin ItalyMaria Grazia MILIA 1 , Francesco CERUTTI 1 , Gabriella GREGORI 1 ,Elisa BURDINO 1 , Tina RUGGIERO 1 , Tiziano ALLICE 1 , AlexPROIETTI 1 , Barbara SIMONCELLI 1 , Filippo LIPANI 2 , Gianni DIPERRI 2 , Valeria GHISETTI 11 Laboratory of Microbiology and Virology, Infectious Diseases Department,Amedeo di Savoia Hospital, Torino, ITALY; 2 Department ofInfectious Diseases, Amedeo di Savoia Hospital and University of Torino,Torino, ITALYBackground/Aim: Enteroviruses (EVs) are RNA viruses causing a varietyof diseases, including aseptic meningitis. Recent EVs aseptic meningitisoutbreaks have been reported in European countries. We report an outbreakof aseptic meningitis from October 18th to November 2nd, 2012 involving10 adult patients in the area of Turin, North Western Italy.Methods: All patients were parents or close relatives of children aged
Page 3 and 4:
Contents5 th European Congress of V
Page 5 and 6:
i r o l o g i eList of Keynote Spea
Page 7 and 8:
i r o l o g i eList of Chairpersons
Page 9 and 10:
i r o l o g i eWelcomeWelcome to th
Page 11 and 12:
5 th European Congress of VirologyY
Page 13 and 14:
i r o l o g i eExhibitorsThe indust
Page 15:
i r o l o g i eFacilities for the 5
Page 18 and 19:
i r o l o g i eGeneral Information
Page 20 and 21:
PROGRAMME AT A GLANCEWednesday 11th
Page 22 and 23:
5 th European Congress of VirologyW
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Scientific Programme -Saturday 14 t
Page 34 and 35:
5 th European Congress of Virology1
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
5 th European Congress of VirologyT
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
5 th European Congress of VirologyR
Page 56 and 57:
Page 58 and 59:
5 th European Congress of Virologyw
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
5 th European Congress of Virologyt
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
5 th European Congress of VirologyA
Page 72 and 73:
5 th European Congress of Virologyp
Page 74 and 75:
Page 76 and 77:
5 th European Congress of VirologyF
Page 78 and 79:
Page 80 and 81:
5 th European Congress of Virologyc
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
5 th European Congress of VirologyH
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
5 th European Congress of VirologyS
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Virologie 2013, 17 (supplément 2)
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
5 th European Congress of VirologyH
Page 128 and 129:
5 th European Congress of Virologys
Page 130 and 131:
Page 132 and 133:
5 th European Congress of Virologyf
Page 134 and 135:
5 th European Congress of VirologyE
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
5 th European Congress of Virologyi
Page 146 and 147:
5 th European Congress of Virologyr
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
5 th European Congress of VirologyB
Page 162 and 163:
5 th European Congress of Virologyr
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
5 th European Congress of VirologyI
Page 170 and 171:
Page 172 and 173:
5 th European Congress of Virologya
Page 174 and 175:
Page 176 and 177: 5 th European Congress of Virology1
Page 178 and 179: 5 th European Congress of Virologyt
Page 180 and 181: 5 th European Congress of VirologyV
Page 182 and 183: 5 th European Congress of Virologyc
Page 184 and 185: 5 th European Congress of Virologyw
Page 188 and 189: 5 th European Congress of Virologya
Page 190 and 191: 5 th European Congress of VirologyA
Page 192 and 193: 5 th European Congress of Virologyn
Page 194 and 195: 5 th European Congress of Virologyi
Page 198 and 199: 5 th European Congress of VirologyT
Page 200 and 201: 5 th European Congress of Virology(
Page 206 and 207: 5 th European Congress of Virologyo
Page 208 and 209: 5 th European Congress of VirologyI
Page 210 and 211: 5 th European Congress of VirologyR
Page 218 and 219: 5 th European Congress of Virologyp
Page 222 and 223: 5 th European Congress of Virology(
Page 230 and 231: 5 th European Congress of Virologyo
Page 244 and 245: 5 th European Congress of Virologyc
Page 248 and 249: 5 th European Congress of Virologyh
Page 252 and 253: 5 th European Congress of VirologyC
Page 254 and 255: 5 th European Congress of VirologyM
Page 260 and 261: 5 th European Congress of Virologyf
Page 266 and 267: 5 th European Congress of VirologyM
Page 268 and 269: 5 th European Congress of VirologyI
Page 270 and 271: 5 th European Congress of Virologyp
Page 272 and 273: 5 th European Congress of Virologyu
Page 274 and 275: 5 th European Congress of VirologyO
Page 276 and 277:
5 th European Congress of Virologys
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
5 th European Congress of VirologyI
Page 288 and 289:
5 th European Congress of VirologyB
Page 290 and 291:
5 th European Congress of VirologyD
Page 292 and 293:
5 th European Congress of VirologyG
Page 294 and 295:
5 th European Congress of VirologyJ
Page 296 and 297:
5 th European Congress of VirologyL
Page 298 and 299:
5 th European Congress of VirologyN
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
show all

rologie i - European Congress of Virology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?